
Moderna’s combo flu-COVID shot shows durable immune response in mid-stage trial
Moderna reported that its experimental mRNA-1073 two-in-one flu and COVID-19 vaccine elicited durable immune responses against matched influenza and SARS-CoV-2 strains for six months in a small 550-participant mid-stage trial, with no serious safety concerns; the briefing also covers ongoing Potomac River contamination concerns after a wastewater spill, a long-term MSU study showing college students rebounded emotionally post-pandemic, and other health news highlights.













